Iceland’s Landspítali Awards ISK 1.6 Billion Immunoglobulin Procurement to Multiple Pharmaceutical Suppliers Materials and Products

Standfirst

Iceland’s national university hospital has completed a pharmaceutical procurement covering immunoglobulin medicines with a reported total award value of ISK 1.6 billion. The award notice identifies Icepharma and Alvogen ehf and Vistor among the successful tenderers. The procurement was conducted as an open procedure and the contracts have a duration of two years. The structure gives several suppliers a role in supplying the hospital rather than concentrating the reported awards with a single company.

Introduction

Reliable access to specialised medicines is a procurement issue with consequences that extend well beyond purchasing departments. For a university hospital such as Landspítali the availability of essential pharmaceutical products must be supported by dependable commercial arrangements because interruptions can affect clinical services and patient treatment.

That requirement is reflected in Iceland’s latest procurement for immunoglobulin medicines. The contract award notice covers pharmaceutical products under the title “Ýmis lyf 87 Immúnoglóbúlín”. The procurement is classified as supplies and uses CPV 33600000 for pharmaceutical products. The place of performance is the Höfuðborgarsvæði region of Iceland.

The award is notable because the notice records multiple successful tenderers within the same lot. Icepharma is identified with the tender reference connected to CSL Behring. Alvogen ehf is identified with its own tender reference. Vistor appears as the winner for several tender references connected with Takeda and Octapharma and Accord for Prothya Biosolution.

The reported value of all contracts awarded in the notice is ISK 1.6 billion. At the same time the individual tender records shown in the notice carry a tender value of ISK 0.00. The distinction is important because the published aggregate award value should not be assigned to any single supplier without additional information from the contracting documentation.

Why This Contract Matters

The procurement matters because immunoglobulins are specialised pharmaceutical products used in hospital care and reliable supply is an important operational requirement. A public hospital cannot treat pharmaceutical purchasing as an ordinary commodity transaction when shortages or supply disruptions can create pressure on clinical planning.

The award also provides an insight into supplier participation in Iceland’s hospital pharmaceutical market. Rather than identifying one successful company across the procurement the notice records several winners within LOT-0000. This suggests that the procurement structure allowed different tenderers to secure contracts associated with different product or supplier references.

The two year duration gives the hospital a defined procurement horizon while giving successful suppliers visibility over the period covered by their contracts. The notice does not disclose a separate financial value for each successful contract in the available award information.

Another important signal is the absence of a framework agreement. The procurement is recorded as a direct award result rather than a framework arrangement with future call offs. That makes the published award more directly relevant to the contracts concluded on 09/06/2026.

Contract Timeline

The procurement carries internal identifier 35055 and procedure identifier d4843f7e-34c1-4b28-a508-c09a8cbd228b. The procedure was conducted as an open procedure and was not accelerated. The stated legal basis is Directive 2014/24/EU.

The successful suppliers were selected on 09/06/2026. The contracts identified in the award information were also concluded on 09/06/2026.

The award notice was dispatched on 10/09/2026. It was published as OJ S 176/2026 on 11/09/2026 under notice number 628398-2026.

Contract Overview

The procurement titled “Ýmis lyf 87 Immúnoglóbúlín” concerns pharmaceutical products for Landspítali University Hospital. The notice describes the requirement as a tender for various drugs with further description contained in the tender documents available electronically through the Mercell Tendsign procurement portal.

The procurement has one identified lot named LOT-0000. The lot has the same title as the overall procedure and carries the internal identifier 35055.

The reported value of all contracts awarded through the notice is ISK 1.6 billion. The published individual tender entries show ISK 0.00 which indicates that a supplier specific financial figure is not available through those entries. The notice therefore supports the aggregate award value but does not support allocating that full amount to any one winner.

Key Contract Details

Project Scope

The scope covers the supply of pharmaceutical products under the immunoglobulin procurement. The notice describes the requirement broadly as various drugs with detailed product information contained in the electronic tender documentation.

The procurement is located within the Höfuðborgarsvæði region of Iceland. The use of CPV 33600000 places the contract within the broader pharmaceutical products category rather than a general hospital supply category.

The award structure includes five successful tender records within LOT-0000. The published tender identifiers connect individual awards with Icepharma and Alvogen ehf and Vistor and references to CSL Behring and Takeda and Octapharma and Accord for Prothya Biosolution.

About the Contracting Authority

Landspítali Háskólasjúkrahús is the buyer and the organisation signing the contracts. The notice classifies the buyer as a body governed by public law and identifies health as its contracting activity.

Its role in this procurement is to secure pharmaceutical supplies for the university hospital through a regulated public procurement process. The same organisation is recorded as the contracting organisation for the successful contracts.

About the Organisations Involved

Landspítali Háskólasjúkrahús is the buyer and the organisation signing the contracts. It initiated the procurement for pharmaceutical products and is responsible for the contractual relationship with the successful tenderers.

Icepharma is identified as a successful tenderer for LOT-0000. Its tender identifier is “Ýmis lyf 87/CSL Behring” and the corresponding contract identifier is 100. The notice classifies the economic operator as micro small or medium.

Alvogen ehf is also identified as a successful tenderer for LOT-0000. Its tender identifier is “Alvogen ehf_Ymis lyf 87” and its contract identifier is 102. The notice also classifies Alvogen ehf as a micro small or medium economic operator.

Vistor is identified as a successful tenderer for LOT-0000 in several award entries. The notice records tender identifiers connected with Takeda and Octapharma and Accord for Prothya Biosolution. Contract identifiers associated with these entries include 103 and 105 and 107. The notice classifies Vistor as a micro small or medium economic operator.

CSL Behring appears within the tender identifier associated with Icepharma. The notice does not separately assign CSL Behring a buyer role or a direct winning bidder role. Its precise commercial relationship to the awarded supply is not established by the award notice.

Takeda appears within a tender identifier associated with Vistor. The notice does not separately identify Takeda as the contracting party or successful tenderer.

Octapharma appears within a tender identifier associated with Vistor. The notice does not establish a separate contractual role for Octapharma beyond its appearance in the tender identifier.

Accord appears within the tender identifier “Ýmis lyf 87 Accord fyrir hönd Prothya Biosolution”. The notice does not provide sufficient information to assign a separate contractual responsibility to Accord or Prothya Biosolution.

Prothya Biosolution is named in the Vistor tender identifier. The available notice information does not establish whether it is a manufacturer or supplier or another commercial participant in the specific awarded arrangement.

Kærunefnd útboðsmála is the review organisation named in the notice. It also provides information concerning the review procedures. Its role is related to procurement review and not pharmaceutical supply.

Mercell Holding ASA is identified as the TED eSender. The notice records its role in transmitting the procurement notice into the TED publication system. The procurement description also refers to the Mercell Tendsign procurement portal as the electronic location for tender documents.

Procurement Analysis

The procurement used an open procedure under Directive 2014/24/EU. An open procedure allows eligible suppliers to submit tenders without a separate preselection stage and is a standard approach for competitive public purchasing.

The notice records five tenders received for LOT-0000. That provides evidence of competition within the procurement although the published award data does not disclose the comparative financial scores or the identities of unsuccessful tenderers in the result information reviewed.

The award criteria are not fully described in the award notice. The notice identifies a quality criterion and states that its name and description are available in the invitation to tender and tender documents. It therefore would not be appropriate to infer a specific price weighting or technical weighting from the award notice alone.

The multi winner structure is commercially significant. Instead of treating the lot as a single supplier award the result identifies multiple contracts with different successful tenderers. This can support a diversified supply base but the notice does not explain the precise allocation of medicines between suppliers.

Additional Procurement Facts

The procurement was not financed with EU funds and it is not covered by the Government Procurement Agreement. It also does not use a framework agreement or a dynamic purchasing system.

The notice records zero complainants. Subcontracting is recorded as no for the tender entries identified in the award information. The review deadline information refers tenderers to the tender documents.

Market & Industry Perspective

The award provides a useful view of pharmaceutical procurement in a relatively concentrated national market. The combination of several successful suppliers and five received tenders shows that competition can exist even when the underlying requirement involves specialised medicines.

The most important market signal is the use of several contract awards within one lot. This means suppliers should not automatically interpret a large pharmaceutical procurement as a winner takes all competition. The result indicates that different tender submissions can lead to separate contractual outcomes within the same procurement structure.

For pharmaceutical distributors the commercial challenge extends beyond the product itself. Suppliers need dependable sourcing and regulatory compliance and inventory planning and delivery capability because hospital purchasing depends on continuity as much as on the initial tender response.

The references to CSL Behring and Takeda and Octapharma and Accord for Prothya Biosolution also show how supplier identifiers can reveal product or commercial relationships that are not separately described in the award notice. Businesses should treat such references as procurement signals rather than assume a formal role that the notice does not establish.

Economic Significance

The reported aggregate value of all contracts awarded in the notice is ISK 1.6 billion. That figure demonstrates the scale of the pharmaceutical purchasing requirement addressed through this procurement.

Because the individual tender entries record ISK 0.00 it is not possible from the award notice to calculate the financial share received by each successful supplier. The ISK 1.6 billion figure should therefore be treated as the aggregate value reported by TED and not as revenue guaranteed to any particular company.

Future Procurement Opportunities

The two year duration creates a clear monitoring horizon for pharmaceutical suppliers. As the contracts approach expiry businesses should watch for new procurement notices from Landspítali Háskólasjúkrahús involving immunoglobulins or related pharmaceutical categories.

The strongest monitoring signal is CPV 33600000. Suppliers can use this classification to identify future pharmaceutical procurement activity connected with the hospital and the wider Icelandic public sector.

Businesses should also monitor any new procurement that uses the same or a related title and internal identifier structure. A future procurement could change the product scope or supplier participation or evaluation model and the current award provides a useful baseline for comparison.

The next opportunity may not necessarily reproduce the current multi winner structure. That will depend on future tender documentation and the hospital’s purchasing requirements and the competitive market at the time of the next procurement.

Opportunities for Suppliers

Suppliers seeking to compete in this market should build a detailed understanding of hospital pharmaceutical demand before the next procurement is released. The current award shows that several companies can secure contracts within one procurement and that supplier participation should be assessed at the individual tender level.

Companies should also examine their ability to maintain product availability throughout a two year contract period. Inventory planning and dependable manufacturer relationships and regulatory readiness can become important commercial strengths even where the published award notice does not disclose the detailed technical criteria.

International pharmaceutical companies can also examine local market access through established Icelandic suppliers. The appearance of international pharmaceutical names within tender identifiers suggests that domestic tenderers can be linked to wider pharmaceutical supply arrangements although the precise relationships should be confirmed through tender documentation.

What Businesses Should Watch

Businesses should watch Landspítali Háskólasjúkrahús for future pharmaceutical procurement notices as the current two year contracts move toward their end date. A new tender could provide the next major entry point for suppliers seeking Icelandic hospital business.

They should also monitor CPV 33600000 and related pharmaceutical classifications. Tracking the buyer together with the relevant CPV code can provide earlier visibility than relying only on the procurement title.

The allocation of future requirements between suppliers is another important signal. The current notice records Icepharma and Alvogen ehf and Vistor as successful tenderers with multiple Vistor entries. Future notices should be examined carefully to determine whether this structure continues.

Finally businesses should distinguish between the aggregate award value and individual supplier values. The current notice reports ISK 1.6 billion for all contracts while the tender records show ISK 0.00. That reporting pattern makes supplier level revenue analysis impossible without additional procurement information.

TendersOnTime.com Procurement Intelligence

This procurement represents a broader trend in public healthcare purchasing toward securing access to specialised medicines through structured competition and multiple supplier participation. The strategic importance lies not only in the ISK 1.6 billion aggregate value but also in the way one pharmaceutical requirement produced several successful contractual relationships. For suppliers this means the competitive landscape should be analysed at the product and tender level rather than through a simple single winner model.

The strongest lesson for pharmaceutical businesses is preparation around supply capability. A supplier entering this market should understand the hospital’s purchasing categories and maintain dependable product availability and prepare the evidence required by the tender documents well before publication. The notice itself does not disclose enough information to determine which technical or commercial features separated the winning bids so suppliers should not assume that price alone decided the outcome.

The award also demonstrates why procurement intelligence needs to connect supplier names with tender identifiers and contract identifiers. Vistor appears across several successful tender entries while Icepharma and Alvogen ehf also appear as winners. The references to CSL Behring and Takeda and Octapharma and Accord for Prothya Biosolution provide additional market signals but the notice does not establish their precise contractual responsibilities.

Looking ahead the next procurement cycle could provide valuable evidence on whether Iceland’s hospital pharmaceutical market continues to use multiple suppliers for specialised medicine categories. Businesses should therefore monitor Landspítali Háskólasjúkrahús and CPV 33600000 and future notices linked with immunoglobulin products. Early tracking will help suppliers understand changing demand and identify opportunities before the next award is published.

Supplier Takeaways

• Landspítali Háskólasjúkrahús is the buyer and contracting organisation.
• The procurement covers pharmaceutical products with a focus on immunoglobulin medicines.
• LOT-0000 is the identified lot.
• The main CPV code is 33600000.
• The procedure used was an open procedure.
• Directive 2014/24/EU is the stated legal basis.
• The contract duration is two years.
• Five tenders were received.
• Zero complainants were recorded.
• Icepharma is identified as a successful tenderer.
• Alvogen ehf is identified as a successful tenderer.
• Vistor is identified as a successful tenderer across multiple tender entries.
• The reported aggregate award value is ISK 1.6 billion.
• Individual tender entries record ISK 0.00.
• Supplier specific financial allocations are therefore not disclosed in the award information.
• No framework agreement was used.
• No dynamic purchasing system was used.
• The procurement was not financed with EU funds.
• The procurement is not covered by the GPA.

Key Takeaways

• Iceland has completed a significant hospital pharmaceutical procurement for immunoglobulin medicines.
• Landspítali Háskólasjúkrahús signed the resulting contracts.
• The notice reports ISK 1.6 billion as the value of all contracts awarded.
• The procurement contains one identified lot named LOT-0000.
• Five tenders were received.
• Multiple suppliers were selected as winners.
• Icepharma won a contract linked with CSL Behring.
• Alvogen ehf won a contract under its own tender identifier.
• Vistor won multiple contracts linked with Takeda and Octapharma and Accord for Prothya Biosolution.
• The notice does not establish separate contractual roles for CSL Behring and Takeda and Octapharma and Accord and Prothya Biosolution.
• The individual tender values are recorded as ISK 0.00.
• The aggregate notice value must not be allocated to individual suppliers without supporting evidence.
• The contracts were concluded on 09/06/2026.
• The notice was published on 11/09/2026.
• CPV 33600000 should be monitored for future pharmaceutical procurement opportunities.

Conclusion

The Landspítali pharmaceutical award places ISK 1.6 billion of reported public procurement value behind a two year supply arrangement for immunoglobulin medicines. The multi supplier outcome involving Icepharma and Alvogen ehf and Vistor provides a useful view of how competition can be structured in specialised hospital pharmaceutical purchasing.

For suppliers the main opportunity is to use the award as a market intelligence reference point. Future competition will depend on the hospital’s requirements and the tender documents and the structure of the next procurement.

Source: Tenders Electronic Daily (TED) Contract Award Notice 628398-2026 Official Journal of the European Union OJ S 176/2026 published on 11/09/2026.